Holen Sie sich die Stockscreener-App
14.49
7.81%
1.05
Handel nachbörslich:
14.70
0.21
+1.45%
Schlusskurs vom Vortag:
$13.44
Offen:
$13.67
24-Stunden-Volumen:
1.27M
Relative Volume:
0.76
Marktkapitalisierung:
$1.42B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-30.83
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
+0.42%
1M Leistung:
+3.35%
6M Leistung:
+3.35%
1J Leistung:
+64.29%
1-Tages-Spanne:
$13.54
$14.54
1-Wochen-Bereich:
$13.28
$14.87
52-Wochen-Spanne:
$7.55
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Vergleichen Sie SPRY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
14.49 | 1.52B | 0 | -44.84M | -44.23M | -0.47 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com
Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals - WBFF
Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
BNP Paribas Financial Markets Purchases New Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ProShare Advisors LLC Buys 3,436 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $354,000 Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Deutsche Bank AG Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Neffy provides needle-free relief to those with allergic reactions - KOIN.com
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
ARS Pharmaceuticals Leadership Takes Stage at 3 Major Investment Conferences This June - Stock Titan
D. E. Shaw & Co. Inc. Decreases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals: neffy - WCIV
Exploring US High Growth Tech Stocks In May 2025 - simplywall.st
Brent Saunders Sells 120,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus
Expert Dr. Chase shares insights on Neffy for summer allergy season - KOKH
FY2025 EPS Estimates for SPRY Cut by Cantor Fitzgerald - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Leerink Partnrs Has Bearish Outlook for SPRY Q2 Earnings - Defense World
William Blair Brokers Lower Earnings Estimates for SPRY - Defense World
Needle-Free Emergency Epinephrine Now Available for Pediatric Patients - Dermatology Advisor
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 10.8% – Still a Buy? - Defense World
Price T Rowe Associates Inc. MD Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Call Transcript - MSN
ARS Pharmaceuticals targets 80% commercial coverage for neffy in 2025 while expanding pediatric reach - MSN
Ars Pharmaceuticals’ Neffy Launch Boosts Market Prospects - TipRanks
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates - MSN
What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today - Yahoo Finance
Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15% - simplywall.st
ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launc - GuruFocus
Dimensional Fund Advisors LP Has $2.07 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals Reports Strong Q1 2025 Performance - TipRanks
SPRY Reports Q1 Revenue Surpassing Expectations, Preps for Key M - GuruFocus
ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launch in Q1 2025 - GuruFocus
ARS Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: ARS Pharmaceuticals Q1 2025 revenue beats forecast - Investing.com Nigeria
Transcript : ARS Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
ARS Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $8.0M, EPS Misses at -$0.35 - GuruFocus
ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million - marketscreener.com
ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq
ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates - marketscreener.com
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) - The Manila Times
ARS Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ARS Pharmaceuticals Reports First Quarter 2025 Financial - GlobeNewswire
ARS Pharma Q1 Earnings: First Needle-Free Epinephrine Spray Hits $7.8M Revenue, 57% Insurance Coverage - Stock Titan
ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
ARS Pharma’s epinephrine nasal spray 1mg now available in US - Yahoo
Neffy Maker Steps Up Awareness for MDs; Launches Kids’ Device - Allergic Living
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
2.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):